Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial
- PMID:21041839
- DOI: 10.1093/ntr/ntq191
Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial
Abstract
Introduction: Dianicline is a α4β2 nicotinic acetylcholine receptor partial agonist, a class of drugs that includes varenicline and cytisine. Varenicline is efficacious for smoking cessation, while cytisine has not been studied systematically. The efficacy of dianicline has not been previously tested in an adequately powered study.
Methods: In a randomized, double-blind, parallel group placebo-controlled trial, 602 generally healthy cigarette smokers were assigned to dianicline (n = 300) or placebo (n = 302) for 7 weeks followed by a 19-week off drug follow-up period.
Results: Exhaled carbon monoxide and cotinine-confirmed continuous abstinence rates for Weeks 4-7 were 24.0% for dianicline versus 20.5% for placebo (odds ratio 1.22; 95% CI, 0.83-1.80; p = .307). For Weeks 4-26, the abstinence rates were 16.7% for dianicline versus 13.9% for placebo (odds ratio 1.24; 95% CI, 0.79-1.93; p = .366). Craving for a cigarettes was reduced by dianicline compared with placebo after 7 weeks (p = .0175). Nicotine withdrawal symptoms measured by the Hughes and Hatsukami Minnesota Withdrawal Scale were lower for dianicline compared with placebo in the first 3 weeks of treatment during which time quit rates were also higher in the dianicline-treated group.
Conclusions: Dianicline did not increase cigarette smoking abstinence rates beyond the initial phase of treatment. However, self-reported craving and nicotine withdrawal symptoms were reduced.
Similar articles
- Nicotine receptor partial agonists for smoking cessation.Cahill K, Stead LF, Lancaster T.Cahill K, et al.Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103. doi: 10.1002/14651858.CD006103.pub6.Cochrane Database Syst Rev. 2012.Update in:Cochrane Database Syst Rev. 2016 May 09;(5):CD006103. doi: 10.1002/14651858.CD006103.pub7.PMID:22513936Updated.Review.
- The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.Rollema H, Hurst RS.Rollema H, et al.Psychopharmacology (Berl). 2018 Sep;235(9):2479-2505. doi: 10.1007/s00213-018-4921-9. Epub 2018 Jul 7.Psychopharmacology (Berl). 2018.PMID:29980822Review.
- Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group.Gonzales D, et al.JAMA. 2006 Jul 5;296(1):47-55. doi: 10.1001/jama.296.1.47.JAMA. 2006.PMID:16820546Clinical Trial.
- A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, Williams KE.Tsai ST, et al.Clin Ther. 2007 Jun;29(6):1027-39. doi: 10.1016/j.clinthera.2007.06.011.Clin Ther. 2007.PMID:17692719Clinical Trial.
- Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group.Jorenby DE, et al.JAMA. 2006 Jul 5;296(1):56-63. doi: 10.1001/jama.296.1.56.JAMA. 2006.PMID:16820547Clinical Trial.
Cited by
- Nicotinic receptors in airway disease.Borkar NA, Thompson MA, Bartman CM, Khalfaoui L, Sine S, Sathish V, Prakash YS, Pabelick CM.Borkar NA, et al.Am J Physiol Lung Cell Mol Physiol. 2024 Feb 1;326(2):L149-L163. doi: 10.1152/ajplung.00268.2023. Epub 2023 Dec 12.Am J Physiol Lung Cell Mol Physiol. 2024.PMID:38084408Free PMC article.Review.
- Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation.Mohamed TS, Jayakar SS, Hamouda AK.Mohamed TS, et al.Front Mol Neurosci. 2015 Nov 25;8:71. doi: 10.3389/fnmol.2015.00071. eCollection 2015.Front Mol Neurosci. 2015.PMID:26635524Free PMC article.Review.
- Nicotine receptor partial agonists for smoking cessation.Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N.Livingstone-Banks J, et al.Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.Cochrane Database Syst Rev. 2023.PMID:37142273Free PMC article.Review.
- Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.Aubin HJ, Luquiens A, Berlin I.Aubin HJ, et al.Br J Clin Pharmacol. 2014 Feb;77(2):324-36. doi: 10.1111/bcp.12116.Br J Clin Pharmacol. 2014.PMID:23488726Free PMC article.Review.
- The nicotinic acetylcholine receptor as a target for antidepressant drug development.Philip NS, Carpenter LL, Tyrka AR, Price LH.Philip NS, et al.ScientificWorldJournal. 2012;2012:104105. doi: 10.1100/2012/104105. Epub 2012 Apr 24.ScientificWorldJournal. 2012.PMID:22619570Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical